BERNE, Switzerland--(BUSINESS WIRE)--Kenta Biotech has presented positive Phase IIa results of its lead drug candidate, panobacumab (KBPA101), with all patients completing the treatment for hospital-acquired pneumonia (HAP) and ventilator-acquired pneumonia (VAP) caused by P. aeruginosa achieving an effective clearance of pneumonia as well as a 100% survival rate. Panobacumab, a fully human IgM monoclonal antibody, is a first-in-class immunotherapy for these life-threatening infections, and this clinical trial reveals its potential as a more effective treatment than standard antibiotic therapy alone.
